AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25826767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CP and SC)
Number of subjects: 772
Study 23788305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 14
Study 20517305 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (3,600 billion CFU/day)
Number of subjects: 144
Study 20517305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 17936283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched transfer medium (HETM)
Number of subjects: 1282
Study 17936283 — intervention group
Group type: COMPARATOR
Intervention: Conventional embryo transfer medium
Number of subjects: 1282
Study 16093516 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment
Number of subjects: 47
Study 16093516 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care waitlist (Control)
Number of subjects: 47
Study 14508327 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (5 mg/kg)
Number of subjects: 38
Study 14508327 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 38
Study 10662918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar forearm flap
Number of subjects: 67
Study 10662918 — intervention group
Group type: COMPARATOR
Intervention: Radial forearm flap
Number of subjects: 67
Study 9037361 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 1.0 microgram/kg s.c. daily for 3‐7 days followed by CEOP with filgrastim support 10 micrograms/kg s.c. daily, day 2‐14
Number of subjects: 14
Study 9037361 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP chemotherapy (C 500 mg/m2, E 37.5 mg/m2, O 2 mg, P 75 mg/m2)
Number of subjects: 14
Study 9037361 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP chemotherapy (C 750 mg/m2, E 50 mg/m2, O 2 mg, P 75 mg/m2)
Number of subjects: 14
Study 9037361 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim support
Number of subjects: 14
Study 9037361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 14
Study 1577056 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 5 mg.kg-1 per day with omeprazole 20 mg per day
Number of subjects: 8
Study 1577056 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 5 mg.kg-1 per day with placebo
Number of subjects: 8
Study 3000412 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus ACNU (100 mg/m2 on day 1 and 42)
Number of subjects: 105
Study 3000412 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus ACNU and tegafur (400 mg/m2, daily for 8 weeks)
Number of subjects: 105
Study 3000412 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 105
Study 3000412 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus ACNU
Number of subjects: 105
Study 29193478 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvacrol capsule (1.2 mg/kg/day) for 2 months
Number of subjects: 23
Study 29193478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27955648 — intervention group
Group type: EXPERIMENTAL
Intervention: Statewide health promotion intervention in primary schools
Number of subjects: 1943
Study 27955648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1943
Study 23744488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleuran (β-glucan from Pleurotus ostreatus)
Number of subjects: 0
Study 23744488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22974220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 50
Study 22974220 — intervention group
Group type: COMPARATOR
Intervention: Non-Tourniquet
Number of subjects: 50
Study 20451896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed valve implant (model FP7; 184 mm² surface area)
Number of subjects: 92
Study 20451896 — intervention group
Group type: COMPARATOR
Intervention: Molteno single-plate implant (134 mm² surface area)
Number of subjects: 92
Study 20451896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 18630765 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% 10 mL epidurally
Number of subjects: 40
Study 18630765 — intervention group
Group type: COMPARATOR
Intervention: piritramide 0.08 mg kg(‐1) i.v.
Number of subjects: 40
Study 15839958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carboplatin and paclitaxel
Number of subjects: 0
Study 15839958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal therapy
Number of subjects: 0
Study 15839958 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance/consolidation therapy
Number of subjects: 0
Study 15839958 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a third non-cross-resistant drug to carboplatin and paclitaxel
Number of subjects: 0
Study 11886010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) treatment
Number of subjects: 3825
Study 9987087 — intervention group
Group type: COMPARATOR
Intervention: 60 mg FU plus a sham infusion
Number of subjects: 9
Study 9987087 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg FU plus 200 ml of a 20% solution of HA
Number of subjects: 9
Study 9987087 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion plus 200 ml of a 20% solution of HA
Number of subjects: 9
Study 7561818 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills training
Number of subjects: 132
Study 7561818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 132
Study 7561818 — intervention group
Group type: COMPARATOR
Intervention: Twelve Step recovery
Number of subjects: 132
Study 2075482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (MSP)
Number of subjects: 0
Study 2075482 — intervention group
Group type: COMPARATOR
Intervention: Lariam (MEF)
Number of subjects: 0
Study 7027893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg (group A) b.i.d for 12 weeks
Number of subjects: 55
Study 7027893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 25 mg (group B) b.i.d for 12 weeks
Number of subjects: 55
Study 7027893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose combination of hydrochlorothiazide with metoprolol
Number of subjects: 55
Study 30381901 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (approximately 25 g of protein from 125 g per week of sardine, advised to restrict carbohydrate intake)
Number of subjects: 94
Study 30381901 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet (1,800 kcal) with nutritional counselling to follow national nutrition guidelines (15% protein, 60% carbohydrates, and 25% lipids)
Number of subjects: 94
Study 30381901 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 94
Study 27853891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (500 mg daily oral administration, n = 103)
Number of subjects: 197
Study 27853891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 94)
Number of subjects: 197
Study 27853891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1
Number of subjects: 197
Study 27853891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 25646809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and standardised behavioural strategies delivered by trained psychologists or trainee paediatricians during two fortnightly consultations and a follow‐up telephone call
Number of subjects: 244
Study 25646809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and standardised behavioural strategies
Number of subjects: 244
Study 24422876 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based physiotherapy intervention (B)
Number of subjects: 600
Study 24422876 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy-based physiotherapy intervention (C)
Number of subjects: 600
Study 24422876 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control - A)
Number of subjects: 600
Study 20948461 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior multilevel vertebral osteotomy (PMVO)
Number of subjects: 13
Study 19263013 — intervention group
Group type: EXPERIMENTAL
Intervention: 2005 CPR guidelines
Number of subjects: 49
Study 19263013 — intervention group
Group type: COMPARATOR
Intervention: 2000 CPR guidelines
Number of subjects: 49
Study 17075367 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% saline in 6% hydroxyethyl starch (HSS)
Number of subjects: 22
Study 17075367 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 22
Study 14702492 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (aimed at providing 1800 mg of Ca/day)
Number of subjects: 67
Study 14702492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable from calcium-containing liquid)
Number of subjects: 67
Study 14702492 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 67
Study 14702492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 22
Study 11720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index (RMI)
Number of subjects: 22
Study 11720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living Scale (NEADL)
Number of subjects: 22
Study 11720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenchay Activities Index (FAI)
Number of subjects: 22
Study 9211770 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque 270 mg I/ml)
Number of subjects: 2452
Study 9211770 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (Ultravist 300 mg I/ml)
Number of subjects: 2452
Study 7962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Men whose partners experience unexplained recurrent spontaneous abortion
Number of subjects: 0
Study 7962398 — intervention group
Group type: COMPARATOR
Intervention: Men whose partners have normal reproductive histories
Number of subjects: 0
Study 7962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Men whose partners have cellular immunity to sperm antigens
Number of subjects: 0
Study 3610514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine solution
Number of subjects: 100
Study 3610514 — intervention group
Group type: COMPARATOR
Intervention: povidone-iodine vaginal suppositories
Number of subjects: 100
Study 3610514 — intervention group
Group type: COMPARATOR
Intervention: 0.2% aluminium acetate solution
Number of subjects: 100
Study 31411950 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus Pemetrexed and Carboplatin (Gef+C)
Number of subjects: 350
Study 31411950 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (Gef)
Number of subjects: 350
Study 29042177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 20
Study 29042177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29042177 — intervention group
Group type: EXPERIMENTAL
Intervention: Any change in antibiotic exposure
Number of subjects: 20
Study 27827949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia + carbohydrate supplementation (6% carbohydrate solution, maltodextrin)
Number of subjects: 7
Study 27827949 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 7
Study 27827949 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 7
Study 25511050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral squamous cell carcinoma (OSCC) patients
Number of subjects: 30
Study 25511050 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy volunteers)
Number of subjects: 30
Study 22283392 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened population (n = 1705)
Number of subjects: 4936
Study 22283392 — intervention group
Group type: COMPARATOR
Intervention: Unscreened population (n = 1705)
Number of subjects: 4936
Study 22283392 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened population
Number of subjects: 4936
Study 22283392 — intervention group
Group type: COMPARATOR
Intervention: Unscreened population
Number of subjects: 4936
Study 21524564 — intervention group
Group type: EXPERIMENTAL
Intervention: CFVR measurement during adenosine-induced hyperemia in the left anterior descending artery, left circumflex artery, and posterior descending artery.
Number of subjects: 108
Study 21524564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined echocardiographic criteria (pCFVR <2.0 or retrograde coronary artery flow).
Number of subjects: 108
Study 21524564 — intervention group
Group type: EXPERIMENTAL
Intervention: CFVR measurement in the mid to distal left anterior descending artery.
Number of subjects: 108
Study 18023439 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (0.2 mg SC) in addition to hCG (5,000 U) 34 hours before oocyte aspiration
Number of subjects: 221
Study 18023439 — intervention group
Group type: COMPARATOR
Intervention: hCG (5,000 U) 34 hours before oocyte aspiration (Control group)
Number of subjects: 221
Study 17056947 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 110
Study 17056947 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 110
Study 14724722 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education (four 1-hour sessions of group education)
Number of subjects: 85
Study 14724722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 85
Study 11034651 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK/C fusion cage(s)
Number of subjects: 344
Study 11034651 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy with uninstrumented bone‐only fusion)
Number of subjects: 344
Study 11034651 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 344
Study 11034651 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK/C
Number of subjects: 344
Study 11034651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BAK/C and ACDF
Number of subjects: 344
Study 8681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging (thallium imaging)
Number of subjects: 0
Study 8681017 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide studies
Number of subjects: 0
Study 8681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive testing
Number of subjects: 0
Study 8681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic variables (thallium imaging)
Number of subjects: 0
Study 1433581 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with prophylactic antibacterials
Number of subjects: 306
Study 1433581 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 306
Study 4080137 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety treatment group
Number of subjects: 39
Study 4080137 — intervention group
Group type: COMPARATOR
Intervention: Low anxiety treatment group
Number of subjects: 39
Study 4080137 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial questioning
Number of subjects: 39
Study 4080137 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety content of questions
Number of subjects: 39
Study 31531962 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 31531962 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 29458278 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 29458278 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0
Study 29458278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29458278 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg and 75 mg
Number of subjects: 0
Study 26984932 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy
Number of subjects: 443
Study 24998572 — intervention group
Group type: EXPERIMENTAL
Intervention: KHRA-based counseling
Number of subjects: 332
Study 24998572 — intervention group
Group type: COMPARATOR
Intervention: Conventional counseling
Number of subjects: 332
Study 23013162 — intervention group
Group type: EXPERIMENTAL
Intervention: One week multidisciplinary inpatient self-management programme (SMP)
Number of subjects: 150
Study 23013162 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 150
Study 20672296 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID) for up to nine courses (28 days on/28 days off)
Number of subjects: 274
Study 20672296 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID)
Number of subjects: 274
Study 17133181 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA+
Number of subjects: 36
Study 17133181 — intervention group
Group type: COMPARATOR
Intervention: DAA-
Number of subjects: 36
Study 14767021 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-derived S/D ratio >1.33
Number of subjects: 118
Study 11518836 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring using the Omron HEM‐702 monitor
Number of subjects: 40
Study 11518836 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure monitoring by project nurse
Number of subjects: 40
Study 11518836 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 40
Study 11518836 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring and clinic blood pressure monitoring
Number of subjects: 40
Study 9890718 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer concentration on the third postoperative day in patients with DVT (n = 47)
Number of subjects: 118
Study 9890718 — intervention group
Group type: COMPARATOR
Intervention: D-dimer concentration on the third postoperative day in patients without DVT (n = 64)
Number of subjects: 118
Study 9890718 — intervention group
Group type: COMPARATOR
Intervention: D-dimer concentrations pre-operatively and at the time of phlebography
Number of subjects: 118
Study 8032546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously once weekly (4 doses, stratum I)
Number of subjects: 28
Study 8032546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously three times a week every other day (9 doses, stratum II)
Number of subjects: 28
Study 8032546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously five times a week every other week (10 doses, stratum III)
Number of subjects: 28
Study 2583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal
Number of subjects: 6
Study 2583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciplar
Number of subjects: 6
Study 2583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Corbeta
Number of subjects: 6
Study 2583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propal
Number of subjects: 6
Study 1091171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral colistin sulfate (non-absorbable broad-spectrum antimicrobial)
Number of subjects: 0
Study 1091171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31150087 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX intervention (behavioral counseling strategy integrating motivational interviewing and problem-solving skills training)
Number of subjects: 258
Study 31150087 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX intervention
Number of subjects: 258
Study 31150087 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 258
Study 29184759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothenar fat pad flap (HTFPF)
Number of subjects: 37
Study 29184759 — intervention group
Group type: COMPARATOR
Intervention: Conventional open carpal tunnel release (COR)
Number of subjects: 37
Study 29184759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HTFPF and COR
Number of subjects: 37
Study 26142837 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 30
Study 26142837 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 23356250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime juice treatment
Number of subjects: 113
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Wok size 36 cm with handle angle -20°
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Wok size 39 cm
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Wok size 42 cm
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle angle 25°
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle angle 10°
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle angle -5°
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle angle -20°
Number of subjects: 12
Study 22020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle angle -35°
Number of subjects: 12
Study 19657201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconitum napellus C30
Number of subjects: 27
Study 19657201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16732082 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 2 Macintosh curved blade (MCB)
Number of subjects: 100
Study 16732082 — intervention group
Group type: COMPARATOR
Intervention: No. 3 Macintosh curved blade (MCB)
Number of subjects: 100
Study 15618379 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography and short MR imaging examination
Number of subjects: 87
Study 15618379 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 87
Study 15618379 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative MR imaging results
Number of subjects: 87